RxDoctor Payments Data

Patrick Grogan

Neurology · Lackland A F B, TXNPI 1801815147

Payments from drug & device makers

$33,027in general payments, 2019–2025

Across 1,980 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$4K
  • UCB, Inc.$3K
  • Acadia Pharmaceuticals Inc$3K
  • Neurocrine Biosciences, Inc.$2K
  • Acorda Therapeutics, Inc$1K
  • Medtronic$1K
  • plus $19K from 54 others

What the payments were for

  • Speaking & faculty fees$3321%
  • Food & beverage$32,66599%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.338$4,019
UCB, Inc.132$2,743
Acadia Pharmaceuticals Inc221$2,618
Neurocrine Biosciences, Inc.102$1,752
Acorda Therapeutics, Inc67$1,257
Medtronic(2 entities)42$1,147
AbbVie(2 entities)71$1,141
Amneal Pharmaceuticals LLC73$1,124
Neurelis, Inc.41$1,123
Abbott43$978
Lilly USA, LLC60$875
Lundbeck LLC43$813
MDD US Operations, LLC27$806
Kyowa Kirin, Inc.46$750
Nevro Corp.9$738
Catalyst Pharmaceuticals, Inc.32$612
GE HealthCare40$606
Eisai Inc.35$603
EMD Serono, Inc.59$595
Pfizer25$502
Novartis34$485
Sunovion Pharmaceuticals Inc.36$473
Amgen24$472
Supernus Pharmaceuticals, Inc.48$432
Argenx US, Inc.18$421
Grifols USA, LLC18$411
CSL Behring20$393
Adamas Pharmaceuticals, Inc.37$391
Octapharma USA, Inc.16$355
SK Life Science, Inc.28$340
AstraZeneca(2 entities)15$317
Upsher-smith Laboratories LLC17$278
Johnson & Johnson9$238
Merz Pharmaceuticals, LLC7$235
Amylyx Pharmaceuticals, Inc.12$223
Takeda Pharmaceuticals U.S.A., Inc.11$215
Tanabe Pharma America, Inc.9$196
Biogen10$188
Alnylam Pharmaceuticals Inc.8$178
Biohaven Pharmaceuticals, Inc.6$172
Corium, LLC7$157
Scilex Pharmaceuticals Inc.9$151
Promius Pharma LLC2$150
Biohaven Pharmaceutical Holding Company Ltd.10$148
Avion Pharmaceuticals7$138
Azurity Pharmaceuticals, Inc.6$109
Merz North America, Inc.6$102
Globus Medical1$101
Averitas Pharma Inc.5$97
Axsome Therapeutics, Inc.4$86
Jazz Pharmaceuticals Inc.4$73
GRT US Holding, Inc.5$71
Otsuka America Pharmaceutical, Inc.3$55
Shire North American Group Inc3$52
Arbor Pharmaceuticals, Inc.3$44
Vertical Pharmaceuticals, LLC3$40
Life Molecular Imaging Ltd2$31
Vanda Pharmaceuticals Inc.1$27
Dynasplint Systems Inc.1$26
Microtransponder, Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,027 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$162,008
Medicare patients
438
Services billed
7,448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$240,227
OctagamImmun Globg(Igg)/Malt/Iga Ov5033$142,909
Aimovig AutoinjectorErenumab-Aooe12$9,086
Gabapentin157$4,972
Mycophenolate Mofetil18$2,590
Diphenhydramine Hcl32$2,445
Baclofen28$1,439
Memantine Hcl29$1,439
Pyridostigmine Bromide15$1,265
Pregabalin56$784
Famotidine31$773
Carbidopa-LevodopaCarbidopa/Levodopa33$531
Ondansetron Hcl18$523
Sodium Chloride0.9 % Sodium Chloride29$432
Duloxetine Hcl21$327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$215$240,22712 claims
PfizerOctagam$502$142,90933 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil, Pyridostigmine Bromide$1,124$3,85533 claims
Upsher-smith Laboratories LLCTopiramate$278$23011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.

Other neurology in Lackland A F B

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →